Logo

UCB Entered into a Co-Development and Co-Commercialization Agreement with Novartis for UCB0599 to Treat Parkinson's Disease

Share this
UCB Entered into a Co-Development and Co-Commercialization Agreement with Novartis for UCB0599 to Treat Parkinson's Disease

UCB Entered into a Co-Development and Co-Commercialization Agreement with Novartis for UCB0599 to Treat Parkinson's Disease

Shots:

  • UCB to receive $150M up front and is eligible to receive milestones upon regulatory approvals and achievement of development and sales-related milestones with a total consideration of $1.5B. The alliance will co-develop & co-fund the development of UCB0599 globally
  • The agreement will combine UCB's expertise with Novartis' global capabilities & deep experience in transformative disease-modifying treatments to expand the development of UCB0599 for PD
  • UCB will be the marketing authorization holder & commercial lead in the EU & Japan while Novartis in the US & other countries & gets the right for the co-development of UCB7853 upon completion of the P-I program

 Ref: PR Newswire | Image: Novartis 

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions